Drug intelligence / Profile preview

Daclaxen

Development stage: Unknown
Lead developer: Everest Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Daclaxen is a direct-acting antiviral (DAA) medication containing daclatasvir, developed and marketed by Everest Pharmaceuticals in Bangladesh. It is indicated for the treatment of chronic hepatitis C virus (HCV) infection, typically used in combination with other antiviral agents such as sofosbuvir. Daclatasvir functions as a highly selective inhibitor of the HCV non-structural protein 5A (NS5A), which is essential for viral RNA replication and the assembly of new virions. By targeting NS5A, Daclaxen effectively disrupts the viral life cycle, leading to a significant reduction in viral load and high rates of sustained virologic response (SVR) in patients with various HCV genotypes.

Brand names: Daclaxen
Other names: daclatasvir

Targets

NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))

Beyond the preview

Go deeper on Daclaxen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Daclaxen.

Explore the full profile